Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone-moxifloxacin after cataract surgery
NCT05428683Completed
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of triamcinolone and Moxisurge in endophthalmitis and post-operative inflammation. Primary endpoints: Best Corrected Visual Acuity at 3 months and Condition of the eye without use of topical medications at 3 months. Started Dec 2020; status: completed.
02
Drugs
triamcinoloneMoxisurge
03
Conditions
endophthalmitispost-operative inflammation
Beyond the preview
Go deeper on NCT05428683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428683.